<html><head></head><body><h1>Methenamine, Sodium Phosphate Monobasic, Phenyl Salicylate, Methylene Blue, and Hyoscyamine</h1><ul class="ddc-anchor-links"><li>Uses</li>
<li>Contraindications</li>
<li>Dosage</li>
<li>Storage</li>
<li>Interactions</li>
<li>Warnings</li>
<li>Pregnancy</li>
<li>Patient education</li></ul><h2>Pronunciation</h2><p>(meth EN a meen, SOW dee um FOS fate mon oh BAY sik, fen nil sa LIS i late, METH i leen bloo, &amp; hye oh SYE a meen)</p><h2>Index Terms</h2><ul><li>Hyoscyamine, Methenamine, Methylene Blue, Phenyl Salicylate, and Sodium Phosphate Monobasic</li><li>Hyoscyamine, Methenamine, Sodium Phosphate Monobasic, Phenyl Salicylate, and Methylene Blue</li><li>Meth/Meblue/Sod Phos/Psal/Hyos</li><li>Methen/M-Blue/Sal/Na Phos/Hyos</li><li>Methylene Blue, Methenamine, Sodium Phosphate Monobasic, Phenyl Salicylate, and Hyoscyamine</li><li>Mth/Me Blue/Sod Phos/Phen/Hyos</li><li>Phenyl Salicylate, Methenamine, Methylene Blue, Sodium Biphosphate, and Hyoscyamine</li><li>Sodium Phosphate Monobasic, Methenamine, Methylene Blue, Phenyl Salicylate, and Hyoscyamine</li></ul><h2>Dosage Forms</h2><p>Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p><p>Capsule, oral:</p><p>Azuphen MB: Methenamine 120 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 36 mg, methylene blue 10 mg, hyoscyamine sulfate 0.12 mg [DSC]</p><p>Uramit MB: Methenamine 118 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 36 mg, methylene blue 10 mg, hyoscyamine sulfate 0.12 mg [DSC]</p><p>Uribel: Methenamine 118 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 36 mg, methylene blue 10 mg, hyoscyamine sulfate 0.12 mg</p><p>UroAv-B: Methenamine 118 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 36 mg, methylene blue 10 mg, hyoscyamine sulfate 0.12 mg</p><p>Uro-MP: Methenamine 118 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 36 mg, methylene blue 10 mg, hyoscyamine sulfate 0.12 mg</p><p>Ustell: Methenamine 120 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 36 mg, methylene blue 10 mg, hyoscyamine sulfate 0.12 mg</p><p>Uticap: Methenamine 120 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 36 mg, methylene blue 10 mg, hyoscyamine sulfate 0.12 mg</p><p>Vilamit MB: Methenamine 118 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 36 mg, methylene blue 10 mg, hyoscyamine sulfate 0.12 mg</p><p>Tablet, oral:</p><p>Hyolev MB: Methenamine 81 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 32.4 mg, methylene blue 10.8 mg, hyoscyamine sulfate 0.12 mg [DSC]</p><p>Phosphasal: Methenamine 81.6 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 36.2 mg, methylene blue 10.8 mg, hyoscyamine sulfate 0.12 mg</p><p>Ur N-C: Methenamine 81.6 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 36.2 mg, methylene blue 10.8 mg, hyoscyamine sulfate 0.12 mg [DSC]</p><p>Urelle: Methenamine 81 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 32.4 mg, methylene blue 10.8 mg, hyoscyamine sulfate 0.12 mg</p><p>Uretron D/S: Methenamine 81.6 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 36.2 mg, methylene blue 10.8 mg, hyoscyamine sulfate 0.12 mg</p><p>Urimar-T: Methenamine 120 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 36.2 mg, methylene blue 10.8 mg, hyoscyamine sulfate 0.12 mg</p><p>Urin DS: Methenamine 81.6 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 36.2 mg, methylene blue 10.8 mg, hyoscyamine sulfate 0.12 mg</p><p>Uro-458: Methenamine 81 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 32.4 mg, methylene blue 10.8 mg, hyoscyamine sulfate 0.12 mg</p><p>UroAv-81: Methenamine 81 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 32.4 mg, methylene blue 10.8 mg, hyoscyamine sulfate 0.12 mg</p><p>Utira-C: Methenamine 81.6 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 36.2 mg, methylene blue 10.8 mg, hyoscyamine sulfate 0.12 mg</p><p>Utrona-C: Methenamine 81.6 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 36.2 mg, methylene blue 10.8 mg, hyoscyamine sulfate 0.12 mg</p><p>Vilevev MB: Methenamine 81 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 32.4 mg, methylene blue 10.8 mg, hyoscyamine sulfate 0.12 mg</p><h2>Brand Names: U.S.</h2><ul><li>Azuphen MB [DSC]</li><li>Hyolev MB [DSC]</li><li>Phosphasal</li><li>Ur N-C [DSC]</li><li>Uramit MB [DSC]</li><li>Urelle</li><li>Uretron D/S</li><li>Uribel</li><li>Urimar-T</li><li>Urin DS</li><li>Uro-458</li><li>Uro-MP</li><li>UroAv-81</li><li>UroAv-B</li><li>Ustell</li><li>Uticap</li><li>Utira-C</li><li>Utrona-C</li><li>Vilamit MB</li><li>Vilevev MB</li></ul><h2>Pharmacologic Category</h2><ul><li>Antibiotic, Miscellaneous</li></ul><h2 class="ddc-anchor-offset" id="uses">Use: Labeled Indications</h2><p>Treatment of symptoms of irritative voiding; relief of local symptoms associated with urinary tract infections; relief of urinary tract symptoms caused by diagnostic procedures</p><h2 class="ddc-anchor-offset" id="contraindications">Contraindications</h2><p>Hypersensitivity to methenamine, hyoscyamine, methylene blue, or any component of the formulation.<b> Note:</b> Contraindications to methenamine and hyoscyamine may also apply; see Methenamine and Hyoscyamine individual monographs for more information.</p><h2 class="ddc-anchor-offset" id="dosage">Dosing: Adult</h2><p><b>Urinary tract symptoms:</b> Oral: One tablet 4 times daily (follow by liberal fluid intake)</p><h2>Dosing: Geriatric</h2><p>Avoid use (Beers Criteria [AGS 2019]).</p><h2>Dosing: Pediatric</h2><p><b>Urinary tract symptoms: </b>Children &gt;6 years: Oral: Dosage must be individualized</p><h2 class="ddc-anchor-offset" id="storage">Storage</h2><p>Store at controlled room temperature of 15°C to 30°C (59°F to 86°F).</p><h2 class="ddc-anchor-offset" id="interactions">Drug Interactions</h2><p>Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Monitor therapy</i></p><p>Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Agents with Blood Glucose Lowering Effects: Monoamine Oxidase Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. <i> Monitor therapy</i></p><p>Alcohol (Ethyl): May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Avoid combination</i></p><p>Alosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Monitor therapy</i></p><p>Alpha-/Beta-Agonists (Indirect-Acting): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting). While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details. <i> Avoid combination</i></p><p>Alpha1-Agonists: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details. <i> Avoid combination</i></p><p>Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Monitor therapy</i></p><p>Amantadine: Urinary Acidifying Agents may decrease the serum concentration of Amantadine. <i> Monitor therapy</i></p><p>Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Monitor therapy</i></p><p>Amphetamines: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Amphetamines. While linezolid and tedizolid may interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to monographs specific to those agents for details. <i> Avoid combination</i></p><p>Antacids: May diminish the therapeutic effect of Methenamine. Management: Consider avoiding this combination if possible. Antacids may decrease the therapeutic effects of methenamine; sodium bicarbonate is of most concern. If coadministering methenamine and antacids, monitor for decreased methenamine efficacy.<i> Consider therapy modification</i></p><p>Antacids: May decrease the serum concentration of Hyoscyamine. Management: Administer immediate release hyoscyamine before meals and antacids after meals when these agents are given in combination.<i> Consider therapy modification</i></p><p>Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Monitor therapy</i></p><p>Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Monitor therapy</i></p><p>Antipsychotic Agents: Serotonergic Agents (High Risk) may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. <i> Monitor therapy</i></p><p>Apraclonidine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Apraclonidine. Monoamine Oxidase Inhibitors may increase the serum concentration of Apraclonidine. <i> Avoid combination</i></p><p>AtoMOXetine: Monoamine Oxidase Inhibitors may enhance the neurotoxic (central) effect of AtoMOXetine. <i> Avoid combination</i></p><p>Atropine (Ophthalmic): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Atropine (Ophthalmic). <i> Avoid combination</i></p><p>BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Avoid combination</i></p><p>BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Monitor therapy</i></p><p>Benzhydrocodone: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Management: The use of benzhydrocodone is not recommended for patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation. If coadministration is required, use test doses and frequent titration of small benzhydrocodone.<i> Consider therapy modification</i></p><p>Beta2-Agonists: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Beta2-Agonists. <i> Monitor therapy</i></p><p>Betahistine: Monoamine Oxidase Inhibitors may increase the serum concentration of Betahistine. <i> Monitor therapy</i></p><p>Bezafibrate: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Bezafibrate. <i> Avoid combination</i></p><p>Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Monitor therapy</i></p><p>Brimonidine (Ophthalmic): Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Brimonidine (Ophthalmic). Monoamine Oxidase Inhibitors may increase the serum concentration of Brimonidine (Ophthalmic). <i> Monitor therapy</i></p><p>Brimonidine (Topical): Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Brimonidine (Topical). Monoamine Oxidase Inhibitors may increase the serum concentration of Brimonidine (Topical). <i> Monitor therapy</i></p><p>Buprenorphine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Avoid combination</i></p><p>BuPROPion: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of BuPROPion. <i> Avoid combination</i></p><p>BusPIRone: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Avoid combination</i></p><p>Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Monitor therapy</i></p><p>CarBAMazepine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Management: Avoid concurrent use of carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.<i> Avoid combination</i></p><p>Carbonic Anhydrase Inhibitors: May diminish the therapeutic effect of Methenamine. Management: Consider avoiding this combination. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.<i> Consider therapy modification</i></p><p>Cerebrolysin: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Monitor therapy</i></p><p>Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Monitor therapy</i></p><p>Chlorphenesin Carbamate: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Monitor therapy</i></p><p>ChlorproPAMIDE: Urinary Acidifying Agents may increase the serum concentration of ChlorproPAMIDE. <i> Monitor therapy</i></p><p>Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Avoid combination</i></p><p>Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Avoid combination</i></p><p>Clemastine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Clemastine. <i> Monitor therapy</i></p><p>CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Consider therapy modification</i></p><p>Cocaine (Topical): May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Monitor therapy</i></p><p>Codeine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Codeine. <i> Avoid combination</i></p><p>COMT Inhibitors: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Management: Avoid coadministration of COMT inhibitors and nonselective monoamine oxidase inhibitors (MAOIs) (eg, isocarboxazid, phenelzine, tranylcypromine, linezolid, methylene blue) whenever possible.<i> Consider therapy modification</i></p><p>Cyclobenzaprine: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Avoid combination</i></p><p>Cyproheptadine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Cyproheptadine. Cyproheptadine may diminish the serotonergic effect of Monoamine Oxidase Inhibitors. <i> Avoid combination</i></p><p>Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated.<i> Avoid combination</i></p><p>Deutetrabenazine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Deutetrabenazine. <i> Avoid combination</i></p><p>Dexmethylphenidate: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Dexmethylphenidate. <i> Avoid combination</i></p><p>Dextromethorphan: Monoamine Oxidase Inhibitors may enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome. <i> Avoid combination</i></p><p>Diethylpropion: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Diethylpropion. <i> Avoid combination</i></p><p>Dihydrocodeine: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Avoid combination</i></p><p>Diphenoxylate: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Avoid combination</i></p><p>Domperidone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Domperidone. Monoamine Oxidase Inhibitors may diminish the therapeutic effect of Domperidone. Domperidone may diminish the therapeutic effect of Monoamine Oxidase Inhibitors. <i> Monitor therapy</i></p><p>DOPamine: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of DOPamine.  Management: Initiate dopamine at no greater than one-tenth (1/10) of the usual dose in patients who are taking (or have taken within the last 2 to 3 weeks) monoamine oxidase inhibitors. Monitor for an exaggerated hypertensive response to dopamine.<i> Consider therapy modification</i></p><p>Doxapram: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Doxapram. <i> Monitor therapy</i></p><p>Doxylamine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Doxylamine.  Management: The US manufacturer of Diclegis (doxylamine/pyridoxine) and the manufacturers of Canadian doxylamine products specifically lists use with monoamine oxidase inhibitors as contraindicated.<i> Monitor therapy</i></p><p>Droxidopa: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Droxidopa. <i> Avoid combination</i></p><p>Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Avoid combination</i></p><p>EPINEPHrine (Nasal): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of EPINEPHrine (Nasal). <i> Monitor therapy</i></p><p>EPINEPHrine (Oral Inhalation): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of EPINEPHrine (Oral Inhalation). <i> Avoid combination</i></p><p>Epinephrine (Racemic): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Epinephrine (Racemic). <i> Monitor therapy</i></p><p>EPINEPHrine (Systemic): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of EPINEPHrine (Systemic). <i> Monitor therapy</i></p><p>Ergot Derivatives: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Monitor therapy</i></p><p>Esketamine: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Monitor therapy</i></p><p>Fenfluramine: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Avoid combination</i></p><p>Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Monitor therapy</i></p><p>Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Monitor therapy</i></p><p>Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Avoid combination</i></p><p>Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Guanethidine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Avoid combination</i></p><p>Heroin: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Heroin. <i> Avoid combination</i></p><p>HYDROcodone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of HYDROcodone.  Management: Consider alternatives to this combination when possible.<i> Consider therapy modification</i></p><p>HYDROmorphone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of HYDROmorphone. <i> Avoid combination</i></p><p>Indoramin: Monoamine Oxidase Inhibitors may enhance the hypotensive effect of Indoramin. <i> Avoid combination</i></p><p>Iobenguane Radiopharmaceutical Products: Monoamine Oxidase Inhibitors may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Avoid combination</i></p><p>Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Consider therapy modification</i></p><p>Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Consider therapy modification</i></p><p>Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Consider therapy modification</i></p><p>Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Isometheptene: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Isometheptene. <i> Avoid combination</i></p><p>Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Monitor therapy</i></p><p>Ketoconazole (Systemic): Hyoscyamine may decrease the serum concentration of Ketoconazole (Systemic).  Management: Take hyoscyamine at least 2 hours after ingestion of ketoconazole. Monitor for decreased therapeutic effects of ketoconazole if used together with hyoscyamine.<i> Consider therapy modification</i></p><p>Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Monitor therapy</i></p><p>Lasmiditan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Monitor therapy</i></p><p>Levodopa-Containing Products: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI.<i> Avoid combination</i></p><p>Levomethadone: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Avoid combination</i></p><p>Levonordefrin: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Levonordefrin. <i> Avoid combination</i></p><p>Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Avoid combination</i></p><p>Linezolid: Methylene Blue may enhance the serotonergic effect of Linezolid. This could result in serotonin syndrome. <i> Avoid combination</i></p><p>Lithium: Methylene Blue may enhance the serotonergic effect of Lithium. This could result in serotonin syndrome.  Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes).<i> Consider therapy modification</i></p><p>Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Monitor therapy</i></p><p>Maprotiline: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Avoid combination</i></p><p>Mecamylamine: Urinary Acidifying Agents may decrease the serum concentration of Mecamylamine. <i> Monitor therapy</i></p><p>Meptazinol: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Meptazinol. <i> Avoid combination</i></p><p>Mequitazine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Mequitazine. <i> Avoid combination</i></p><p>Metaraminol: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Metaraminol. <i> Monitor therapy</i></p><p>Metaxalone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Monitor therapy</i></p><p>Methadone: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Avoid combination</i></p><p>Methyldopa: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Methyldopa. <i> Avoid combination</i></p><p>Methylphenidate: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Methylphenidate. <i> Avoid combination</i></p><p>Metoclopramide: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Avoid combination</i></p><p>Mianserin: Monoamine Oxidase Inhibitors may enhance the neurotoxic effect of Mianserin. <i> Avoid combination</i></p><p>Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Monitor therapy</i></p><p>Monoamine Oxidase Inhibitors (Antidepressant): May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Avoid combination</i></p><p>Monoamine Oxidase Inhibitors (Type B): May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Avoid combination</i></p><p>Morphine (Systemic): Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Morphine (Systemic). <i> Avoid combination</i></p><p>Nefazodone: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Avoid combination</i></p><p>Nefopam: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Nefopam. <i> Avoid combination</i></p><p>Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Monitor therapy</i></p><p>Norepinephrine: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Norepinephrine. <i> Monitor therapy</i></p><p>Normethadone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Normethadone. <i> Avoid combination</i></p><p>Ondansetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Monitor therapy</i></p><p>Opicapone: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Avoid combination</i></p><p>Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Monitor therapy</i></p><p>Opioid Agonists: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Monitor therapy</i></p><p>Opium: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Opium. <i> Avoid combination</i></p><p>Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Oxitriptan: Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Monitor therapy</i></p><p>OxyCODONE: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Avoid combination</i></p><p>OxyMORphone: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Avoid combination</i></p><p>Ozanimod: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Avoid combination</i></p><p>Pheniramine: May enhance the anticholinergic effect of Monoamine Oxidase Inhibitors.<i> Avoid combination</i></p><p>Pholcodine: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Avoid combination</i></p><p>Pizotifen: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Pizotifen. <i> Avoid combination</i></p><p>Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Avoid combination</i></p><p>Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Avoid combination</i></p><p>Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Avoid combination</i></p><p>Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Monitor therapy</i></p><p>Ramosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Monitor therapy</i></p><p>Reboxetine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Reboxetine. <i> Avoid combination</i></p><p>Remifentanil: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Remifentanil. Specifically, the risk for opioid toxicity (eg, respiratory depression) may be increased. Remifentanil may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.  Management: The use of remifentanil is not recommended for patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation. If coadministration is required, use test doses and titrate small doses of remifentanil frequently.<i> Consider therapy modification</i></p><p>Reserpine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension).  Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine. Monitor closely for paradoxical effects of reserpine (eg, excitation, hypertension).<i> Consider therapy modification</i></p><p>Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Avoid combination</i></p><p>Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Consider therapy modification</i></p><p>Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Avoid combination</i></p><p>Serotonergic Non-Opioid CNS Depressants: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Avoid combination</i></p><p>Serotonergic Opioids (High Risk): Methylene Blue may enhance the serotonergic effect of Serotonergic Opioids (High Risk). This could result in serotonin syndrome.  Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes).<i> Consider therapy modification</i></p><p>Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Monoamine Oxidase Inhibitors may increase the serum concentration of Serotonin 5-HT1D Receptor Agonists (Triptans).<i> Avoid combination</i></p><p>Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Avoid combination</i></p><p>Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Consider therapy modification</i></p><p>Solriamfetol: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Solriamfetol. <i> Avoid combination</i></p><p>St John's Wort: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Monitor therapy</i></p><p>SUFentanil: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Specifically, the risk for serotonin syndrome or opioid toxicities (eg, respiratory depression, coma) may be increased. Management: Sufentanil should not be used with monoamine oxidase (MAO) inhibitors (or within 14 days of stopping an MAO inhibitor) due to the potential for serotonin syndrome and/or excessive CNS depression.<i> Avoid combination</i></p><p>SulfaSALAzine: Methenamine may enhance the adverse/toxic effect of SulfaSALAzine. Specifically, the combination may result in the formation of an insoluble precipitate in the urine. <i> Avoid combination</i></p><p>Sulfonamide Antibiotics: Methenamine may enhance the adverse/toxic effect of Sulfonamide Antibiotics. Specifically, the combination may result in the formation of an insoluble precipitate in the urine. <i> Avoid combination</i></p><p>Syrian Rue: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Monitor therapy</i></p><p>Tapentadol: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Specifically, the additive effects of norepinephrine may lead to adverse cardiovascular effects. Tapentadol may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Avoid combination</i></p><p>Tetrabenazine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Avoid combination</i></p><p>Tetrahydrozoline (Nasal): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Tetrahydrozoline (Nasal). <i> Avoid combination</i></p><p>Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Methenamine.<i> Monitor therapy</i></p><p>Tianeptine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Avoid combination</i></p><p>Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Avoid combination</i></p><p>Tricyclic Antidepressants: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Avoid combination</i></p><p>Tryptophan: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Avoid combination</i></p><p>Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Consider therapy modification</i></p><p>Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Valbenazine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Avoid combination</i></p><h2>Adverse Reactions</h2><p>The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p><p>Frequency not defined.</p><p>Cardiovascular: Flushing, tachycardia</p><p>Central nervous system: Dizziness</p><p>Gastrointestinal: Nausea, vomiting, xerostomia</p><p>Genitourinary: Acute urinary retention, difficulty in micturition, urine discoloration (blue)</p><p>Ophthalmic: Blurred vision</p><p>Respiratory: Dyspnea</p><h2 class="ddc-anchor-offset" id="warnings">Warnings/Precautions</h2><p><b><i>Concerns related to adverse effects:</i></b></p><p>• Belladonna alkaloid allergy: Use with caution in patients with a history of intolerance to belladonna alkaloids.  </p><p>• Blurred vision: Discontinue use immediately if blurred vision occurs.</p><p>• Dizziness: Discontinue use immediately if dizziness occurs.</p><p>• Salicylate allergy: Use with caution in patients with a history of intolerance to salicylates.  </p><p>• Tachycardia: Discontinue use immediately if tachycardia occurs.</p><p><b><i>Disease-related concerns:</i></b></p><p>• Cardiovascular disease: Use with caution in patients with cardiovascular disease (cardiac arrhythmias, HF, coronary heart disease, mitral stenosis).</p><p>• Gastrointestinal tract obstruction: Use with caution in patients with gastrointestinal tract obstruction.</p><p>• Glaucoma: Use with caution in patients with glaucoma.</p><p>• Myasthenia gravis: Use with caution in patients with myasthenia gravis.</p><p>• Obstructive uropathy: Use with caution in patients with obstructive uropathy (bladder neck obstruction or prostatic hyperplasia).</p><p><b><i>Special populations:</i></b></p><p>• Pediatric: Safety and efficacy have not been established in children ≤6 years of age.</p><p><b><i>Other warnings/precautions:</i></b></p><p>• Urine discoloration: May cause urinary discoloration (blue). </p><h2 class="ddc-anchor-offset" id="pregnancy">Pregnancy Risk Factor
C

Pregnancy Considerations</h2><p>Reproduction studies have not been conducted with this combination. Methenamine and hyoscyamine cross the placenta.  </p><h2 class="ddc-anchor-offset" id="patient-education">Patient Education</h2><p><b>What is this drug used for?</b></p><p>• It is used to ease pain from a bladder infection.</p><p>• It is used to treat muscle spasms of the urinary system.</p><p>• It is used to treat urinary signs.</p><p><b>All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:</b></p><p>• Nausea</p><p>• Vomiting</p><p>• Fatigue</p><p>• Dry mouth</p><p>• Urine or stool discoloration</p><p>• Flushing</p><p><b>WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:</b></p><p>• Fast heartbeat</p><p>• Blurred vision</p><p>• Dizziness</p><p>• Shortness of breath</p><p>• Trouble urinating</p><p>• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.</p><p><b>Note:</b> This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.</p><p><b>Consumer Information Use and Disclaimer:</b> This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.</p><h2>More about hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium biphosphate</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>34 Reviews</li>
<li>Drug class: urinary antispasmodics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Hyoscyamine, methenamine, methylene blue, phenyl salicylate, and sodium phosphate &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Urinary Tract Infection</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>